$16.7 million vote of confidence in Melbourne-developed cancer detection system
Posted: 7 August 2023 A major investment in a Melbourne-based healthcare technology developer will underpin the launch of a world-first live microscopic imaging device for oral cancer. Optiscan Imaging Limited (ASX: OIL) has developed a miniaturised, handheld technology…
Immutep Receives Positive Scientific Advice from European Medicines Agency
Posted: 7 August 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive scientific advice from the Committee…
$64 million in funding for new ARC Industrial Transformation Training Centres and ARC Industrial Transformation Research Hubs
Posted: 7 August 2023 More than $64.8 million in funding has been awarded to 8 new Australian Research Council (ARC) Industrial Transformation Training Centres and 5 new ARC Industrial Transformation Research Hubs to mentor and train Australia’s next…
The University of Melbourne and Peter Mac to establish precision cancer care centre
Posted: 2 August 2023 The University of Melbourne and the Peter MacCallum Cancer Centre will establish a new centre to transform how genomics and precision oncology is delivered in Australia. A memorandum of understanding (MoU) to establish the…
Immune cell discovery could lead to improved chronic worm treatment
Posted: 2 August 2023 Monash University researchers have uncovered why some intestinal worm infections become chronic in animal models, which could eventually lead to human vaccines and improved treatments. Parasitic worms, also called helminths, usually infect the host…
Partnered program update
Posted: 1 August 2023 Following communication from AstraZeneca on Friday, 28 July 2023, and the subsequent release of AstraZeneca’s H1 and Q2 2023 results announcement that day, Starpharma (ASX: SPL, OTCQX: SPHRY) reports that AstraZeneca has made the…
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma
Posted: 1 August 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled and safely dosed in…
Scientific breakthrough harnesses mRNA technology to develop powerful malaria vaccine
Posted: 1 August 2023 A new mRNA vaccine targeting immune cells in the liver could be the key to tackling malaria, a disease that causes over half a million deaths each year according to the World Health Organization,…
Advanced Cell Therapy Manufacturing Initiative to be established in Brisbane
Posted: 1 August 2023 CCRM Australia, with its Canadian partners OmniaBio Inc. and Toronto-based CCRM, has signed a Letter of Intent with The University of Queensland to establish the Advanced Cell Therapy Manufacturing Initiative (ACTMI) at the St…
Adherium Enteres Rapid US Commercialisation Phase
Posted: 1 August 2023 Adherium Limited (ASX: ADR), a leading provider of respiratory eHealth, remote monitoring and data management solutions, today announced it is entering a rapid commercialisation phase in reimbursed remote patient monitoring in the globally significant…
Advertising of Health Services – New Advertising Guidelines – Is your advertising compliant?
Posted: 31 July 2023 “This article provides an update on the new Medical Board/AHPRA “Guidelines For Registered Medical Practitioners who Advertise Cosmetic Surgery” which came into effect on 1 July 2023. Health practitioners, individuals, businesses, and companies involved…
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
Posted: 27 July 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) recommended the ATH434-201…
